BERNS PAUL L
SEC CIK 1202769 · EDGAR
BoughtSold
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| KARD | Kardigan, Inc. | Dir, 10% | 15.04M | $20.00M | — | 3 | 2026-06-17 | 2026-06-22 |
| LYEL | Lyell Immunopharma, Inc. | 10% | 1.43M | $12.50M | — | 1 | 2026-03-06 | 2026-03-06 |
| NMRA | Neumora Therapeutics, Inc. | See Remarks, Dir | 7.40M | — | $57.9K | 4 | 2024-02-14 | 2026-02-17 |
| JAZZ | Jazz Pharmaceuticals plc | Dir | 8,290 | — | $223.3K | 1 | 2021-08-05 | 2021-08-05 |
Most active insiders at KARD, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | HRTG GPE, LLC | 10% | $50.00M | — |
| 2 | ARCH Venture Partners XIII, LLC | Dir, 10% | $20.00M | — |
| 3 | BERNS PAUL L | Dir, 10% | $20.00M | — |
| 4 | Edelberg Jay | Chief Medical Off | — | — |
| 5 | Jahn Brianne | CFO | — | — |
| 6 | Pasternak Andy | Chief Strategy Off | — | — |
| 7 | Moriarty John B | CLO | — | — |
| 8 | Giordano Douglas E. | Dir | — | — |
| 9 | GIANAKAKOS ANASTASIOS | Pres, CEO, Dir | — | — |
| 10 | Meeker David P | Dir | — | — |
Transactions 9
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| I | 2026-06-24 16:20 | 2026-06-22 | KARD | Kardigan, Inc. | BERNS PAUL L | Dir, 10% | P - Purchase | $16.00 | +1.25M | 15.04M | +9% | +$20.00M |
| DI | 2026-06-22 19:24 | 2026-06-17 | KARD | Kardigan, Inc. | BERNS PAUL L | Dir, 10% | C - Cnv Deriv | — | +13.79M | 13.79M | New | — |
| D | 2026-06-22 19:24 | 2026-06-17 | KARD | Kardigan, Inc. | BERNS PAUL L | Dir, 10% | A - Grant | $0.00 | +20.7K | 20.7K | New | $0 |
| I | 2026-03-09 | 2026-03-06 | LYEL | Lyell Immunopharma, Inc. | BERNS PAUL L | 10% | P - Purchase | $25.61 | +488.1K | 1.43M | +52% | +$12.50M |
| 2026-02-19 | 2026-02-17 | NMRA | Neumora Therapeutics, Inc. | BERNS PAUL L | See Remarks, Dir | S - Sale | $3.51 | -9,819 | 7.40M | -0.1% | -$34.5K | |
| T | 2025-02-20 | 2025-02-18 | NMRA | Neumora Therapeutics, Inc. | BERNS PAUL L | See Remarks, Dir | S - Sale | $1.69 | -13.9K | 7.41M | -0.2% | -$23.4K |
| M | 2024-12-27 | 2024-12-27 | NMRA | Neumora Therapeutics, Inc. | BERNS PAUL L | Dir | G - Gift | $0.00 | -399.3K | 7.55M | -5% | $0 |
| D | 2024-02-16 | 2024-02-14 | NMRA | Neumora Therapeutics, Inc. | BERNS PAUL L | Dir | A - Grant | $0.00 | +171.2K | 7.82M | +2% | $0 |
| 2021-08-09 | 2021-08-05 | JAZZ | Jazz Pharmaceuticals plc | BERNS PAUL L | Dir | S - Sale | $154.00 | -1,450 | 8,290 | -15% | -$223.3K |
Purchase Sale Sale after option exercise All abbreviations